“Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.”, J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
, “Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.”, Vaccine, vol. 27, no. 37, pp. 5091-5, 2009.
, “Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.”, J Infect Dis, vol. 204, no. 6, pp. 854-63, 2011.
, “Safety and immunogenicity of a candidate parvovirus B19 vaccine.”, Vaccine, vol. 29, no. 43, pp. 7357-63, 2011.
, “Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.”, J Infect Dis, vol. 206, no. 7, pp. 1069-77, 2012.
, “Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial.”, J Infect Dis, vol. 205, no. 5, pp. 703-12, 2012.
, “Rapid research response to the 2009 A(H1N1)pdm09 influenza pandemic (Revised).”, BMC Res Notes, vol. 6, p. 177, 2013.
, “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
, “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
, “Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old.”, J Infect Dis, vol. 212, no. 4, pp. 552-61, 2015.
, “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
, “Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.”, Vaccine, vol. 34, no. 33, pp. 3796-802, 2016.
, ,
“Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.”, Vaccine, vol. 36, no. 5, pp. 606-614, 2018.
, “Safety and immunogenicity of seasonal trivalent inactivated influenza vaccines in pregnant women.”, Vaccine, vol. 36, no. 52, pp. 8054-8061, 2018.
, “Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood.”, Open Forum Infect Dis, vol. 6, no. 1, p. ofy352, 2019.
, “Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination.”, Vaccine, vol. 37, no. 19, pp. 2561-2568, 2019.
, “Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.”, Vaccine, vol. 37, no. 36, pp. 5161-5170, 2019.
, “Safety and immunogenicity of three seasonal inactivated influenza vaccines among pregnant women and antibody persistence in their infants.”, Vaccine, vol. 38, no. 33, pp. 5355-5363, 2020.
, “Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.”, Clin Transl Immunology, vol. 10, no. 1, p. e1239, 2021.
,